How to treat BI-RADS category 3 benign breast disease
Feb 14, 2023
Source: Cainiu Health
Dr. Yu Xiaopeng
Introduction
BI-RADS category 3 breast adenopathy refers to BI-RADS category 3 findings in the breast. Breast BI-RADS category 3 is an imaging term based on the Breast Imaging Reporting and Data System (BI-RADS) classification. Breast lesions classified as BI-RADS 3 are mostly considered benign nodules, although malignancy cannot be entirely ruled out, with a cancer risk of approximately 2%, indicating an indeterminate but probably benign nature.
BIRADS-3 category mastopathy refers to breast lesions classified as BI-RADS 3, a terminology used in radiology based on the Breast Imaging Reporting and Data System (BI-RADS) for categorizing breast findings.
BI-RADS 3 breast lesions are mostly considered benign nodules, although malignancy cannot be entirely ruled out, with a cancer risk of approximately 2%. This classification represents a somewhat indeterminate category, requiring follow-up examinations around every six months. If subsequent imaging shows no increase in nodule size and no abnormal changes in morphology or margins, the lesion is likely benign and typically requires no treatment. However, if the nodule grows rapidly or presents other abnormalities, timely surgical excision should be performed, followed by pathological examination to determine the nature of the nodule.
Clinically, for BI-RADS 3 breast lesions, regular follow-up imaging is generally recommended—specifically ultrasound or mammography every 3 to 6 months—to monitor any changes in the lesion. Surgical intervention or biopsy is usually not indicated at this stage, as medication also tends to be ineffective. If any abnormalities occur, patients should promptly seek evaluation from the Department of General Surgery at a qualified medical institution.
